Galmed stock jumps sky-high on mixed results for NASH drug

Shares in Galmed Pharmaceuticals more than doubled in value Tuesday after the Israeli drugmaker unveiled mid-stage clinical results that the company says show the potential of its experimental liver disease drug aramchol.